The Latest Cardiac and Vascular News
Tustin, Ca, May 01, 2024 (GLOBE NEWSWIRE) — Canon Medical Systems proudly announces the debut installation of the Aquilion Serve SP CT scanner with INSTINX, AI-driven workflow automation, in the United States at Steinberg Diagnostic Medical Imaging (SDMI), Las Vegas, NV. The Aquilion Serve SP CT scanner combines top-tier imaging […]
Caesarea, Israel – April 30, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions through cutting-edge technology, is announcing its partnership with Shandong Yituo Medical Technology Development Co. Ltd. (SYMT), a JMC-invested company. Its new joint venture company, Arineta (Shandong) Medical Equipment Co. Ltd., is anticipating the installation of […]
Award supports design and preclinical testing of Pulmonary Flow Restrictor for Congenital Heart Disease SAN DIEGO, May 1, 2024 /PRNewswire/ — Starlight Cardiovascular, Inc., a company developing pediatric cardiovascular medical devices, announced that it has been awarded a Small Business…
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.
IRVINE, Calif., April 30, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2024.
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024.
Route 92 Medical announces FDA 510(k) clearance for its FreeClimb 54 reperfusion system, part of its growing portfolio of neurovascular devices.
CHAPEL HILL, N.C., April 30, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a patent covering the use of TNX-103 (oral levosimendan), TNX-102 (subcutaneous levosimendan), TNX-101 (IV levosimendan), the active metabolites of levosimendan (OR1896 and OR18955) and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients, entitled: “LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF).”
PALO ALTO, Calif. and MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) — Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced that the first human participants have been dosed in a Phase 1 study of BRB-002 in healthy volunteers. BRB-002 is a novel protein […]
SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection (Eptifibatide) approved by the U.S. Food and Drug Administration. Eptifibatide for Injection is indicated for use in […]
